Inventiva Logo

Inventiva

ISIN: FR0013233012 | Ticker: IVA | LEI: 969500I9Y690B3FZW590
Sector: Health CareSub-Industry: Biotechnology
Country: France

About Inventiva

Company Description

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as a deep pipeline of earlier stage programs.

Year founded

2011

Served area

Worldwide

Headcount

105

Headquarters

50 Rue de Dijon, 21121 Daix – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 56,960,000.00 138,920,000.00 121,985,000.00 116,004,000.00
Noncurrent Assets N/A 8,084,000.00 5,923,000.00 6,408,000.00 9,621,000.00
Property Plant And Equipment N/A 3,721,000.00 3,282,000.00 3,196,000.00 7,385,000.00
Intangible Assets Other Than Goodwill N/A 1,228,000.00 935,000.00 770,000.00 568,000.00
Other Noncurrent Assets N/A 3,135,000.00 1,706,000.00 2,442,000.00 1,668,000.00
Current Assets N/A 48,875,000.00 132,997,000.00 115,578,000.00 106,383,000.00
Inventories N/A 387,000.00 320,000.00 392,000.00 373,000.00
Current Trade Receivables N/A 4,000.00 48,000.00 4,000,000.00 0.00
Cash and cash equivalents 56,692,000.00 35,840,000.00 105,687,000.00 86,553,000.00 86,736,000.00
Other Current Assets N/A 2,811,000.00 17,914,000.00 20,260,000.00 13,267,000.00
Equity And Liabilities N/A 56,960,000.00 138,920,000.00 121,985,000.00 116,004,000.00
Equity 61,596,000.00 41,392,000.00 111,211,000.00 88,866,000.00 45,476,000.00
Issued Capital N/A 268,000.00 386,000.00 409,000.00 421,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A -33,619,000.00 -49,635,000.00 -54,274,000.00
Share Premium N/A 86,012,000.00 139,668,000.00 165,072,000.00 173,886,000.00
Noncurrent Liabilities N/A 1,703,000.00 13,800,000.00 10,266,000.00 39,827,000.00
Noncurrent Provisions For Employee Benefits N/A 1,127,000.00 1,385,000.00 1,429,000.00 1,234,000.00
Other Longterm Provisions N/A 574,000.00 2,377,000.00 0.00 0.00
Noncurrent Contract Liabilities N/A N/A 0.00 0.00 55,000.00
Noncurrent Derivative Financial Liabilities N/A N/A 0.00 0.00 9,876,000.00
Longterm Borrowings N/A 2,000.00 10,037,000.00 8,837,000.00 28,663,000.00
Current Liabilities N/A 13,865,000.00 13,908,000.00 22,853,000.00 30,701,000.00
Current Provisions N/A 1,264,000.00 130,000.00 180,000.00 0.00
Trade And Other Current Payables To Trade Suppliers N/A 7,491,000.00 6,923,000.00 14,602,000.00 19,359,000.00
Current Contract Liabilities N/A N/A 0.00 0.00 6,000.00
Other Current Liabilities N/A 4,998,000.00 6,838,000.00 6,789,000.00 5,485,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 113,000.00 18,000.00 1,282,000.00 5,851,000.00
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 6,998,000.00 372,000.00 4,194,000.00 12,179,000.00
Profit Loss From Operating Activities -30,312,000.00 -29,718,000.00 -52,114,000.00 -57,110,000.00
Finance Income 175,000.00 2,057,000.00 5,478,000.00 4,923,000.00
Finance Costs 81,000.00 5,959,000.00 2,635,000.00 2,107,000.00
Income Tax Expense Continuing Operations 0.00 0.00 364,000.00 -20,000.00
Profit (loss) -30,218,000.00 -33,619,000.00 -49,635,000.00 -54,274,000.00
Line item in (eur) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -30,218,000.00 -33,619,000.00 -49,635,000.00 -54,274,000.00
Adjustments For Income Tax Expense N/A 0.00 0.00 32,000.00 -84,000.00
Adjustments For Decrease Increase In Inventories N/A 22,000.00 68,000.00 -72,000.00 19,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 0.00 3,039,000.00 -5,198,000.00 343,000.00
Adjustments For Sharebased Payments N/A 1,407,000.00 938,000.00 2,089,000.00 2,218,000.00
Adjustments For Fair Value Gains Losses N/A 0.00 -1,791,000.00 651,000.00 407,000.00
Other Adjustments For Noncash Items N/A 0.00 41,000.00 0.00 0.00
Other Inflows Outflows Of Cash Classified As Operating Activities N/A 403,000.00 -2,853,000.00 -1,231,000.00 -1,685,000.00
Cash Flows From Used In Operating Activities N/A -28,404,000.00 -30,590,000.00 -47,629,000.00 -44,928,000.00
Other Inflows Outflows Of Cash Classified As Investing Activities N/A -693,000.00 -571,000.00 -47,000.00 -1,000.00
Cash Flows From Used In Investing Activities N/A -826,000.00 -8,557,000.00 -1,793,000.00 8,868,000.00
Proceeds From Issuing Shares N/A 8,654,000.00 101,782,000.00 25,475,000.00 8,827,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 0.00 9,979,000.00 0.00 30,209,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 146,000.00 61,000.00 13,000.00 1,033,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 130,000.00 26,000.00 15,000.00 735,000.00
Cash Flows From Used In Financing Activities N/A 8,378,000.00 111,674,000.00 25,447,000.00 37,268,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -20,852,000.00 72,527,000.00 -23,975,000.00 1,208,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 -2,681,000.00 4,841,000.00 -1,025,000.00
Cash and cash equivalents 56,692,000.00 35,840,000.00 105,687,000.00 86,553,000.00 86,736,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
08.12.23 None Other Buy EUR 0.00

Capital markets information

ISIN

FR0013233012

LEI

969500I9Y690B3FZW590

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.